Wei Li, MD/PhD
Date:2024-11-21
Chief, Cancer Center
Beijing Tongren Hospital, Capital Medical University, Beijing, China
E-mail: weili8989@ccmu.edu.cn, vision988@126.com

Education
BS, Clinical Medicine, Health Science Center, Peking University
MD/PhD, Rutgers State University of New Jersey, USA
Fellowship training, Johns Hopkins Hospital, Maryland, USA
 
Clinical Specialty
Oncology/Interventional Radiology
 
Research interests
Cancer Immunology/Mechanism & Application of Immunotherapy
Equipment development of interventional oncology (especially tumor ablation systems)

Honors
Beijing High-level Innovational and Enterprising Leading Talents Award (Top tier)
Beijing Talents Project Award
High-level Talented Personnel in Beijing Health System
 
Representative publications
Zhang Y, Chen H, Chen S, Li Z, Chen J, Li W. The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Oncoimmunology. 2021;10(1):1957605.
Li X, Ding X, Li W, Chen J. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure. Cancer Immunol Immunother. 2023;72(6):1395-1403.
Wang Y, Lu X, Wu H, Li W. Gut-homing α4β7 CD4+ T cells: potential key players in both acute HIV infection and HIV-associated cancers. Cell Mol Immunol. 2018;15(2):190-192.
Li W, Henderson LJ, Major EO, Al-Harthi L. IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner. J Immunol. 2011;186(12):6771-8.